Resilient Drug Supply Project Newsletter · Oct 22, 2020
Ensuring a Resilient US Prescription Drug Supply
With lockdowns, shipping delays, and drug needs surging during the pandemic, global drug supply chains are showing vulnerabilities long in the making. In the latest "COVID-19: The CIDRAP Viewpoint," the RDSP team outlines the issues and provides nine key recommendations. Read the report.
Don't have time to read the whole report right now?
News, Publications, and Policies
Pfizer outlines its transportation strategy for its potential COVID-19 vaccine. | Fierce Pharma, Oct 21, 2020
Researchers created an algorithm to optimize healthcare resources across intensive care units using data from the United Kingdom and Spain. | PLOS ONE, Oct 21, 2020
Storage issues could leave 3 billion people around the world without access to a COVID-19 vaccine. | Associated Press, Oct 19, 2020
FDA and CDER announce a new Quality Management Maturity for Finished Dosage Forms Pilot Program that is open to applicable domestic drug product manufacturers. | FDA, Oct 15, 2020
India's and China's reliance on each other for drug ingredients and supplies is coming under strain during the pandemic. | The Lancet Oncology: News, Oct 15, 2020
During a 2018 recall of an angiotensin receptor blocker in Germany, under-prescriptions of hypertensives did not occur, according to a new study. | Journal of Human Hypertension, Oct 14, 2020
Can India use its mother/child immunization program as a foundation to administer a future COVID-19 vaccine? | Quint, Oct 13, 2020
A recent study finds that Germany sources 63% of its APIs from Asia—up 30% from 20 years ago—revealing an increasing reliance on foreign sources. | CIDRAP, Oct 9, 2020
For the latest RDSP news, follow @CIDRAP_RDSP on Twitter.
Recent Drug Shortages (updated Oct 19, 2020)
- 29 (72.5%) of the 40 critical drugs for COVID-19 are in shortage according to ASHP.
- 18 (45%) of the 40 critical drugs for COVID-19 are in shortage according to the FDA.
- ASHP reports the metronidazole shortage as resolved.
- 67 (42.9%, ASHP) and 40 (25.6%, FDA) drugs are in shortage on the 156 Critical Acute Drug List.
Food for Thought
"Markets work, economics work, but often they work only in the long run. When you have a pandemic and shortages of drugs, the problem is in the short run. The cost of waiting for the economic market to work may result in patients not having drugs that can effect their health or even their lives." —Stephen Schondelmeyer, co-PI of RDSP
No comments:
Post a Comment